Chaperonin Modulator Screening via VRK2-COP1 Interaction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for addressing protein aggregation in neurodegenerative diseases like Alzheimer's, Parkinson's, and Huntington's are inadequate, as they often rely on autophagy, which can lead to cell death if not properly controlled, and there is a need for a method to inhibit protein aggregation effectively.
Innovation Solution
A method for screening TRiC/CCT modulators by measuring the expression and enzyme activity of COP1 and VRK2, and their interaction, to identify candidate materials that increase or decrease the stability of chaperonin proteins, thereby preventing protein aggregation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If autophagy is used to remove protein aggregates, then protein aggregate removal is improved, but cell death risk increases due to uncontrolled energy depletion
Solution Approach 1:
Instead of using autophagy to remove aggregates (degradation approach), the invention inverts the strategy by enhancing chaperonin function to prevent aggregate formation in the first place (protection approach). This is achieved by modulating TRiC/CCT chaperonin activity to maintain proper protein folding, thereby avoiding the harmful effects of uncontrolled autophagy while still addressing the aggregate problem.
Solution Approach 2:
The invention applies preliminary action by preventing protein aggregation before it occurs through chaperonin modulation. By enhancing the folding capacity of TRiC/CCT chaperonins, the system proactively prevents misfolding and aggregation, rather than reactively removing aggregates after formation. This preliminary protection avoids the need for potentially harmful autophagic clearance.
2Quantity of substance
If conventional screening methods are used for chaperonin modulators, then screening completeness may be improved, but screening time and complexity increase significantly
Solution Approach 1:
The invention extracts and utilizes the specific interaction between VRK2 kinase and COP1 ubiquitin ligase as a isolated screening marker. By focusing on this particular molecular axis that directly regulates chaperonin stability, the method extracts the essential screening information from the complex cellular environment, enabling rapid identification of modulators without needing to screen all possible protein aggregation pathways.
Solution Approach 2:
The invention introduces VRK2-COP1 interaction as an intermediary marker for screening chaperonin modulators. Instead of directly observing complex chaperonin-aggregate interactions, the method uses the VRK2-COP1 binding event as a mediator that indirectly reports on chaperonin activity status. This intermediary approach simplifies the screening process while maintaining effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the rapid and convenient screening of chaperonin modulators that can effectively prevent or treat neurodegenerative diseases without the risks associated with autophagy, by identifying materials that increase the stability of chaperonin proteins, thus inhibiting protein aggregation.
Implementation Method 1
the VRK2 degrades chaperonin depending on enzyme activity. In the degradation process of chaperonin, ubiquitin ligase COP1 complex interacts with the VRK2
Data Source
Figure 1a~1b
Figure 1c~2a
Figure 2b~2c
AI summary
The present invention relates to a method of screening for modulator of chaperonin that is involved in protein aggregation inducing neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease, use of the chaperonin modulator screened by the method for prevention and treatment of neurodegenerative diseases. According to the present invention, novel negative chaperonin modulator is provided, and chaperonin modulator may be more rapidly and conveniently screened with the negative modulator as a target. Furthermore, by using the screened material, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease may be effectively prevented or treated without concern for cell death due to autophagy, which is the existing method of removing protein aggregate.